Harvard Bioscience, Inc. (HBIO)
USD 2.03
(-6.45%)
USD 2.03
(-6.45%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 30.7 Million USD | -28.62% |
| 2022 | 43.01 Million USD | -4.62% |
| 2021 | 45.09 Million USD | -2.57% |
| 2020 | 46.28 Million USD | -1.34% |
| 2019 | 46.91 Million USD | -20.2% |
| 2018 | 58.79 Million USD | 554.53% |
| 2017 | 8.98 Million USD | -21.02% |
| 2016 | 11.37 Million USD | -30.86% |
| 2015 | 16.45 Million USD | 0.0% |
| 2014 | 16.45 Million USD | -16.71% |
| 2013 | 19.75 Million USD | 52.51% |
| 2012 | 12.95 Million USD | -20.55% |
| 2011 | 16.3 Million USD | -9.49% |
| 2010 | 18 Million USD | 35.32% |
| 2009 | 13.3 Million USD | 22455.93% |
| 2008 | 59 Thousand USD | -98.94% |
| 2007 | 5.57 Million USD | 85.93% |
| 2006 | 3 Million USD | -64.71% |
| 2005 | 8.5 Million USD | -48.55% |
| 2004 | 16.52 Million USD | 29.19% |
| 2003 | 12.78 Million USD | 3097.09% |
| 2002 | 399.96 Thousand USD | -37.23% |
| 2001 | 637.15 Thousand USD | 55692.73% |
| 2000 | 1142.00 USD | -99.98% |
| 1999 | 5.07 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 31.89 Million USD | 3.86% |
| 2024 Q2 | 31.96 Million USD | 0.22% |
| 2023 Q2 | 38.2 Million USD | -7.01% |
| 2023 Q3 | 35.27 Million USD | -7.67% |
| 2023 Q4 | 30.7 Million USD | -12.95% |
| 2023 Q1 | 41.08 Million USD | -4.49% |
| 2023 FY | 30.7 Million USD | -28.62% |
| 2022 Q4 | 43.01 Million USD | -7.57% |
| 2022 FY | 43.01 Million USD | -4.62% |
| 2022 Q1 | 52.4 Million USD | 16.21% |
| 2022 Q2 | 51.57 Million USD | -1.59% |
| 2022 Q3 | 46.53 Million USD | -9.77% |
| 2021 Q3 | 42.74 Million USD | -10.76% |
| 2021 FY | 45.09 Million USD | -2.57% |
| 2021 Q1 | 48.75 Million USD | 5.34% |
| 2021 Q2 | 47.89 Million USD | -1.78% |
| 2021 Q4 | 45.09 Million USD | 5.51% |
| 2020 Q1 | 46.28 Million USD | -1.36% |
| 2020 Q2 | 40.92 Million USD | -11.58% |
| 2020 Q3 | 40.66 Million USD | -0.62% |
| 2020 Q4 | 46.28 Million USD | 13.81% |
| 2020 FY | 46.28 Million USD | -1.34% |
| 2019 FY | 46.91 Million USD | -20.2% |
| 2019 Q2 | 61.12 Million USD | -3.27% |
| 2019 Q1 | 63.19 Million USD | 7.49% |
| 2019 Q4 | 46.91 Million USD | -9.27% |
| 2019 Q3 | 51.71 Million USD | -15.4% |
| 2018 Q1 | 61.56 Million USD | 585.39% |
| 2018 FY | 58.79 Million USD | 554.53% |
| 2018 Q4 | 58.79 Million USD | -0.76% |
| 2018 Q3 | 59.24 Million USD | -0.97% |
| 2018 Q2 | 59.82 Million USD | -2.83% |
| 2017 FY | 8.98 Million USD | -21.02% |
| 2017 Q3 | 9.67 Million USD | -7.13% |
| 2017 Q2 | 10.41 Million USD | -4.7% |
| 2017 Q1 | 10.93 Million USD | -3.89% |
| 2017 Q4 | 8.98 Million USD | -7.14% |
| 2016 Q1 | 14.77 Million USD | -10.2% |
| 2016 FY | 11.37 Million USD | -30.86% |
| 2016 Q3 | 12.66 Million USD | -8.03% |
| 2016 Q2 | 13.77 Million USD | -6.76% |
| 2016 Q4 | 11.37 Million USD | -10.21% |
| 2015 Q3 | 15.15 Million USD | -3.19% |
| 2015 Q1 | 16.9 Million USD | 2.74% |
| 2015 FY | 16.45 Million USD | 0.0% |
| 2015 Q2 | 15.65 Million USD | -7.4% |
| 2015 Q4 | 16.45 Million USD | 8.58% |
| 2014 Q3 | 18.2 Million USD | 5.51% |
| 2014 Q2 | 17.25 Million USD | -6.76% |
| 2014 Q4 | 16.45 Million USD | -9.62% |
| 2014 Q1 | 18.5 Million USD | -6.33% |
| 2014 FY | 16.45 Million USD | -16.71% |
| 2013 FY | 19.75 Million USD | 52.51% |
| 2013 Q4 | 19.75 Million USD | -3.66% |
| 2013 Q3 | 20.5 Million USD | -3.53% |
| 2013 Q2 | 21.25 Million USD | 77.08% |
| 2013 Q1 | 12 Million USD | -7.34% |
| 2012 Q2 | 16.1 Million USD | -4.17% |
| 2012 Q3 | 15.3 Million USD | -4.97% |
| 2012 Q1 | 16.8 Million USD | 3.07% |
| 2012 Q4 | 12.95 Million USD | -15.36% |
| 2012 FY | 12.95 Million USD | -20.55% |
| 2011 FY | 16.3 Million USD | -9.49% |
| 2011 Q4 | 16.3 Million USD | -0.03% |
| 2011 Q3 | 16.3 Million USD | -4.69% |
| 2011 Q2 | 17.1 Million USD | 0.0% |
| 2011 Q1 | 17.1 Million USD | -5.01% |
| 2010 Q1 | 11.8 Million USD | -11.28% |
| 2010 Q2 | 11.15 Million USD | -5.51% |
| 2010 Q3 | 18 Million USD | 61.43% |
| 2010 FY | 18 Million USD | 35.32% |
| 2010 Q4 | 18 Million USD | 0.0% |
| 2009 Q3 | 9 Million USD | 0.0% |
| 2009 Q1 | - USD | -100.0% |
| 2009 FY | 13.3 Million USD | 22455.93% |
| 2009 Q4 | 13.3 Million USD | 47.72% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q3 | 69 Thousand USD | -21.59% |
| 2008 Q1 | 101 Thousand USD | -98.19% |
| 2008 FY | 59 Thousand USD | -98.94% |
| 2008 Q4 | 59 Thousand USD | -14.49% |
| 2008 Q2 | 88 Thousand USD | -12.87% |
| 2007 FY | 5.57 Million USD | 85.93% |
| 2007 Q4 | 5.57 Million USD | 98.72% |
| 2007 Q3 | 2.8 Million USD | 1303.5% |
| 2007 Q2 | 200 Thousand USD | -86.67% |
| 2007 Q1 | 1.5 Million USD | -50.0% |
| 2006 Q4 | 3 Million USD | 0.0% |
| 2006 FY | 3 Million USD | -64.71% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | -100.0% |
| 2005 Q4 | 8.5 Million USD | -41.38% |
| 2005 Q2 | 15.2 Million USD | -0.12% |
| 2005 Q3 | 14.5 Million USD | -4.61% |
| 2005 FY | 8.5 Million USD | -48.55% |
| 2005 Q1 | 15.21 Million USD | -7.88% |
| 2004 FY | 16.52 Million USD | 29.19% |
| 2004 Q4 | 16.52 Million USD | -6.79% |
| 2004 Q3 | 17.72 Million USD | -2.23% |
| 2004 Q1 | 19.38 Million USD | 51.61% |
| 2004 Q2 | 18.12 Million USD | -6.49% |
| 2003 Q3 | 46 Thousand USD | -20.69% |
| 2003 FY | 12.78 Million USD | 3097.09% |
| 2003 Q1 | 348 Thousand USD | -12.99% |
| 2003 Q2 | 58 Thousand USD | -83.33% |
| 2003 Q4 | 12.78 Million USD | 27698.39% |
| 2002 Q1 | 540 Thousand USD | -15.25% |
| 2002 FY | 399.96 Thousand USD | -37.23% |
| 2002 Q2 | 92 Thousand USD | -82.96% |
| 2002 Q4 | 399.96 Thousand USD | 440.49% |
| 2002 Q3 | 74 Thousand USD | -19.57% |
| 2001 FY | 637.15 Thousand USD | 55692.73% |
| 2001 Q2 | 40 Thousand USD | 0.0% |
| 2001 Q3 | 39 Thousand USD | -2.5% |
| 2001 Q1 | - USD | -100.0% |
| 2001 Q4 | 637.15 Thousand USD | 1533.73% |
| 2000 FY | 1142.00 USD | -99.98% |
| 2000 Q4 | 1142.00 USD | 0.0% |
| 1999 FY | 5.07 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 75.25 Million USD | 59.2% |
| AngioDynamics, Inc. | 3.93 Million USD | -679.487% |
| AtriCure, Inc. | 60.59 Million USD | 49.327% |
| Avinger, Inc. | - USD | -Infinity% |
| Azenta, Inc. | 60.43 Million USD | 49.196% |
| BioLife Solutions, Inc. | 18.31 Million USD | -67.681% |
| The Cooper Companies, Inc. | 2.52 Billion USD | 98.783% |
| Daxor Corporation | 755.65 Thousand USD | -3963.208% |
| Ekso Bionics Holdings, Inc. | 4.83 Million USD | -535.43% |
| Femasys Inc. | 4.25 Million USD | -621.059% |
| GlucoTrack, Inc. | 196 Thousand USD | -15565.306% |
| Hologic, Inc. | 2.49 Billion USD | 98.77% |
| ICU Medical, Inc. | 1.57 Billion USD | 98.054% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 137.398% |
| KORU Medical Systems, Inc. | 3.65 Million USD | -740.532% |
| LeMaitre Vascular, Inc. | 16.62 Million USD | -84.697% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 871.7 Million USD | 96.478% |
| Microbot Medical Inc. | 40 Thousand USD | -76660.0% |
| Meihua International Medical Technologies Co., Ltd. | 4592.00 USD | -668541.115% |
| Merit Medical Systems, Inc. | 823.01 Million USD | 96.269% |
| Nephros, Inc. | 1.39 Million USD | -2108.921% |
| NovoCure Limited | 596.24 Million USD | 94.85% |
| NEXGEL, Inc. | 513 Thousand USD | -5885.185% |
| NEXGEL, Inc. | 513 Thousand USD | -5885.185% |
| Singular Genomics Systems, Inc. | 67.52 Million USD | 54.529% |
| OraSure Technologies, Inc. | 11.38 Million USD | -169.617% |
| Pro-Dex, Inc. | 7.53 Million USD | -307.431% |
| Pulse Biosciences, Inc. | 8.08 Million USD | -279.718% |
| Predictive Oncology Inc. | 2.18 Million USD | -1302.663% |
| Precision Optics Corporation, Inc. | 1.93 Million USD | -1484.338% |
| QuidelOrtho Corporation | 2.27 Billion USD | 98.65% |
| Repligen Corporation | 510.14 Million USD | 93.981% |
| Sanara MedTech Inc. | 9.11 Million USD | -236.921% |
| STAAR Surgical Company | 31.46 Million USD | 2.425% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 295 Thousand USD | -10308.136% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 98.29% |
| Jin Medical International Ltd. | - USD | -Infinity% |